Immunic | VTL - Operating Profit


Immunic reported $-23.33M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Alterity Therapeutics Limited AUD -8.07M 302.4K Dec/2025
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Cipla INR 6.14B 3.63B Mar/2026
Clal Biotechnology ILS -1.74M 7.46M Dec/2022
Compugen USD 56.04M 63.93M Dec/2025
CSL USD 2.64B 1.97B Dec/2025
Enanta Pharmaceuticals USD -23.54M 98.15M Dec/2024
Grifols EUR 320.55M 91.01M Dec/2025
Immunic USD -23.33M 2.67M Dec/2025
Insmed USD -200.28M 49.43M Mar/2026
Omeros USD -35.41M 23.75M Sep/2024
OraSure Technologies USD -13.59M 2.13M Dec/2025
Quidel USD -31.8M 5.5M Mar/2026
Ultragenyx Pharmaceutical USD -216M 102M Mar/2026
United Therapeutics USD 325.8M 340.4M Mar/2026
Xoma USD -15.64M 5.56M Sep/2024